David joined the Board of Alliance in April 2014. He was most recently Chief Financial Officer and Chief Business Officer of Biotie Therapies Corp., a drug development copany quoted in Helsinki on the NASDAQ QMX market and in New York on NASDAQ. He has previously held senior financial positions with Jazz Pharmaceuticals Limited, EUSA Pharma Inc., and Zeneus Pharma. David qualified as a Chartered Accountant with PricewaterhouseCoopers after graduating in Chemistry at the University of Oxford.
Biopharma